Filtered By:
Source: Thrombosis and Haemostasis
Condition: Thrombosis
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 27 results found since Jan 2013.
Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice
CONCLUSION: Patients with AF and active cancer experience high rates of thromboembolic and bleeding complications, underlying the complexity of anticoagulant management in these patients. Our data suggest that the presence of cancer is an important factor in determining the indication for anticoagulants in patients with a low CHA2DS2-VASc score.PMID:37063771 | PMC:PMC10099322 | DOI:10.1016/j.rpth.2023.100096
Source: Thrombosis and Haemostasis - April 17, 2023 Category: Hematology Authors: Gordon Chu Jaap Seelig Suzanne C Cannegieter Hans Gelderblom Marcel M C Hovens Menno V Huisman Tom van der Hulle Serge A Trines Andr é J Vlot Henri H Versteeg Martin E W Hemels Frederikus A Klok Source Type: research
Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis
CONCLUSIONS: This study demonstrates that clot-targeted MH can enhance the thrombolysis of contracted human blood clots and can be safely applied to enhance the timeframe in which thrombolysis is effective.PMID:35950914 | DOI:10.1111/jth.15846
Source: Thrombosis and Haemostasis - August 11, 2022 Category: Hematology Authors: David Cabrera Maneea Eizadi Sharifabad Jacob A Ranjbar Neil D Telling Alan G S Harper Source Type: research
Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
In conclusion, this systematic review informs on several potential risk factors and predictors for VTE in people with ischemic stroke. To improve risk stratification and guide development of risk prediction models, further confirmation is needed, as there were few high-quality studies on each factor.PMID:35815351 | DOI:10.1111/jth.15813
Source: Thrombosis and Haemostasis - July 11, 2022 Category: Hematology Authors: Birgitte G T øndel V ânia M Morelli John-Bjarne Hansen Sigrid K Braekkan Source Type: research
Ischemic Stroke with Cancer: Hematologic and Embolic Biomarkers and Clinical Outcomes
CONCLUSIONS: Markers of hypercoagulability and embolic disease may be associated with adverse clinical outcomes in cancer-related stroke.PMID:35652416 | DOI:10.1111/jth.15779
Source: Thrombosis and Haemostasis - June 2, 2022 Category: Hematology Authors: Babak B Navi Cenai Zhang Carla P Sherman Richard Genova Natalie M LeMoss Hooman Kamel Scott T Tagawa Ashish Saxena Allyson J Ocean Scott E Kasner Mary Cushman Mitchell S V Elkind Ellinor Peerschke Lisa M DeAngelis Source Type: research
Previously Undiagnosed Cancer in Patients with Arterial Thrombotic Events - A Population-based Cohort Study
CONCLUSION: There is an increased risk of previously undiagnosed cancer at 12 months after ATE, especially in patients without documented vascular risk factors or pre-existent cardiovascular disease.PMID:34818468 | DOI:10.1111/jth.15600
Source: Thrombosis and Haemostasis - November 24, 2021 Category: Hematology Authors: Avi Leader Noa Dagan Noam Barda Idan Goldberg Pia Raanani Galia Spectre Ran Balicer Anat Gafter-Gvili Source Type: research
Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing 1st-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-paclitaxel
CONCLUSION: Patients with aPC undergoing palliative 1st-line chemotherapy with FOLFIRINOX or GN face a high risk for VTE/ATE and its diagnosis is linked to worse clinical outcomes. VTE-risk prediction models have limited ability to sub-stratify thrombotic events in this high-risk scenario.PMID:34255340 | DOI:10.1055/a-1548-4847
Source: Thrombosis and Haemostasis - July 13, 2021 Category: Hematology Authors: Jakob M Riedl Esther Schwarzenbacher Florian Moik Lena Horvath Antonia Gantschnigg Felix Renneberg Florian Posch Dominik A Barth Michael Stotz Martin Pichler Stefan Hatzl Simon Fandler-H öfler Paul Gressenberger Thomas Gary Philipp Jost Richard Greil Cih Source Type: research
Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination.
PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research
Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
CONCLUSION: In AF patients with malignancy, NOACs appear at least as effective as VKAs in preventing thrombotic events and reduce intracranial bleeding. NOACs may represent a valid and more practical alternative to VKAs in this setting of high-risk patients.
PMID: 31785599 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 29, 2019 Category: Hematology Authors: Cavallari I, Verolino G, Romano S, Patti G Tags: Thromb Haemost Source Type: research
